Yeomans Consulting Group Inc. bought a new stake in Cardinal Health, Inc. (NYSE:CAH - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,922 shares of the company's stock, valued at approximately $316,000.
Several other hedge funds have also recently added to or reduced their stakes in CAH. River Street Advisors LLC acquired a new stake in Cardinal Health in the second quarter worth $288,000. Hilltop National Bank bought a new position in shares of Cardinal Health during the second quarter worth about $236,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Cardinal Health by 2.1% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 32,803 shares of the company's stock valued at $5,511,000 after purchasing an additional 690 shares during the last quarter. Riverview Trust Co grew its holdings in shares of Cardinal Health by 16.9% in the 2nd quarter. Riverview Trust Co now owns 1,037 shares of the company's stock valued at $174,000 after acquiring an additional 150 shares in the last quarter. Finally, CHURCHILL MANAGEMENT Corp boosted its holdings in shares of Cardinal Health by 0.4% in the 2nd quarter. CHURCHILL MANAGEMENT Corp now owns 242,896 shares of the company's stock valued at $40,807,000 after buying an additional 1,057 shares during the last quarter. Institutional investors and hedge funds own 87.17% of the company's stock.
Cardinal Health Stock Up 0.4%
Shares of Cardinal Health stock opened at $158.50 on Friday. Cardinal Health, Inc. has a 12-month low of $106.98 and a 12-month high of $168.44. The company has a market capitalization of $37.66 billion, a price-to-earnings ratio of 24.57, a PEG ratio of 1.34 and a beta of 0.71. The firm's 50-day moving average price is $152.12 and its two-hundred day moving average price is $150.09.
Cardinal Health (NYSE:CAH - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported $2.08 EPS for the quarter, beating the consensus estimate of $2.03 by $0.05. Cardinal Health had a net margin of 0.70% and a negative return on equity of 74.45%. The company had revenue of $60.16 billion during the quarter, compared to analysts' expectations of $60.91 billion. During the same period in the previous year, the company earned $1.84 EPS. The business's revenue for the quarter was up .5% compared to the same quarter last year. Cardinal Health has set its FY 2026 guidance at 9.300-9.500 EPS. On average, sell-side analysts expect that Cardinal Health, Inc. will post 7.95 earnings per share for the current year.
Cardinal Health Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Wednesday, October 1st will be given a dividend of $0.5107 per share. This represents a $2.04 annualized dividend and a dividend yield of 1.3%. The ex-dividend date is Wednesday, October 1st. Cardinal Health's dividend payout ratio is currently 31.63%.
Insider Activity
In other news, insider Michelle D. Greene sold 13,500 shares of the stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $148.82, for a total value of $2,009,070.00. Following the completion of the transaction, the insider owned 14,976 shares of the company's stock, valued at approximately $2,228,728.32. This represents a 47.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Stephen M. Mason sold 41,575 shares of Cardinal Health stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $148.82, for a total transaction of $6,187,191.50. Following the sale, the chief executive officer directly owned 26,085 shares in the company, valued at $3,881,969.70. This trade represents a 61.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 271,676 shares of company stock valued at $40,489,525. Corporate insiders own 0.12% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the company. Argus set a $189.00 target price on Cardinal Health in a report on Friday, August 22nd. Evercore ISI cut their price objective on shares of Cardinal Health from $200.00 to $190.00 and set an "outperform" rating for the company in a research report on Wednesday, August 13th. Robert W. Baird lifted their price target on Cardinal Health from $197.00 to $203.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. Citigroup reaffirmed a "neutral" rating and issued a $170.00 price objective (up from $157.00) on shares of Cardinal Health in a report on Friday, June 13th. Finally, Bank of America lifted their target price on Cardinal Health from $165.00 to $170.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Eleven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $165.93.
View Our Latest Analysis on Cardinal Health
Cardinal Health Profile
(
Free Report)
Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cardinal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardinal Health wasn't on the list.
While Cardinal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.